Klinische Studie Phase II (AMG): COVID-19: CCR1 Antagonist Therapie in hospitalisierten COVID-19 Patienten; Akronym: CATCOVID
| dc.date.accessioned | 2025-09-08T08:28:37Z | |
| dc.date.available | 2025-09-08T08:28:37Z | |
| dc.date.issued | 2024-03-31 | |
| dc.description.abstract | Datei-Upload durch TIB | ger |
| dc.description.version | publishedVersion | |
| dc.identifier.uri | https://oa.tib.eu/renate/handle/123456789/22344 | |
| dc.identifier.uri | https://doi.org/10.34657/21361 | |
| dc.language.iso | ger | |
| dc.publisher | Hannover : Technische Informationsbibliothek | |
| dc.relation.affiliation | Universitätsklinikum Würzburg - Klinik und Poliklinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie | |
| dc.rights.license | Creative Commons Attribution-NonDerivs 3.0 Germany | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nd/3.0/de/ | |
| dc.subject.ddc | 500 | |
| dc.title | Klinische Studie Phase II (AMG): COVID-19: CCR1 Antagonist Therapie in hospitalisierten COVID-19 Patienten; Akronym: CATCOVID | ger |
| dc.title.subtitle | CATCOVID_Verwendungsnachweis_Berichte | |
| dc.type | Report | |
| dcterms.event.date | 01.05.2021 bis 31.12.2023 | |
| dcterms.extent | 6 Seiten | |
| dtf.funding.funder | BMFTR | |
| dtf.funding.program | 16LW0010 | |
| dtf.funding.program | 03LW0010 | |
| dtf.funding.verbundnummer | 01236022 | |
| tib.accessRights | openAccess |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- BMBF16LW0010.pdf
- Size:
- 521.44 KB
- Format:
- Adobe Portable Document Format
- Description: